IMC-R117C for Advanced Cancers
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 600 (estimated)
- Sponsor
- Immunocore Ltd · Industry
This trial is looking for people with certain advanced cancers who are HLA-A*02:01-positive. Participants will receive the IMC-R117C treatment, either on its own or along with other therapies.
You may be able to join if
- I have a performance status score of 0 or 1.
- I am HLA-A*02:01-positive.
- I have been diagnosed with advanced colorectal, esophageal, gastric, or ovarian cancer.
- I can provide an adequate tumor tissue sample.
- I have measurable disease as defined by RECIST 1.1.
- I have received standard treatments for my condition.
- I agree to use effective birth control if I am sexually active.
You may not be able to join if
- I have symptomatic or untreated brain metastasis.
- I have had a recent bowel obstruction.
- I have ongoing fluid build-up that has required recent drainage.
- I have significant ongoing toxicity from previous cancer treatment.
- I have out-of-range laboratory values.
- I have significant lung, heart, or autoimmune disease.
- I need ongoing immunosuppressive treatment.
- I have a significant secondary cancer.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.
Loading trial locations…